The overall freight market activity slowed down significantly compared to the previous year in Q2.
Carlsquare Equity Research har kommenterat förväntningarna inför Future Gamings kv2 rapport den 24 a...
Etteplan’s sales and EBIT from business operations were at EUR 89.
Aspo’s Q2 results fell short of estimates especially due to the loss-making Supramax vessels and cer...
Redeye comments on Freemelt’s Q2 results, which were somewhat better than expected.
Suominen should make further progress towards restoring profitability in H2, however Q2 results rema...
Redeye comments on G5’s Q2-report where topline was somewhat soft while results were close to our fo...
Sales in line, EBIT +11% vs. ABGSCe, FX drivenOrganic growth -10% vs ABGSCe -8.
• Pre-announces Q2, EBITA SEK 14m vs. ABGSCe SEK 28m • Lower profitability in MBXP behind the miss •...
Redeye updates its estimates after reviewing Fantasma Games’ Q2 report, which showed lower growth th...
Ahead of Taaleri's Q2, we adjust our 2023 estimates to reflect the carry from Forest Fund III and ga...
Redeye initiates coverage of Lytix Biopharma, an immuno-oncology company with a Nobel Prize Laureate...
Suominen reported weaker than expected Q2 earnings but continues to anticipate stronger earnings in ...
Redeye provides an update after Gasprox’s Q2’23 report.
Planerar för ny datautläsning Ascelia meddelade under måndagskvällen att de planerar att genomföra e...
Sales and EBITA 2% and 14% vs. ABGSCeCustomer intake flat q-o-q (ABGSCe -2,500)Cons to lift '23e-'25...
Redeye shares its initial thoughts on FlexQube’s Q2 report, which was better than expected top-line-...
Suominen’s Q2 results showed some improvement in terms of operational efficiency, however top line f...
Redeye comments on Gasporox’s Q2’23 report, which was significantly stronger than expected on all it...
Redeye leaves a note following Alzinova's update regarding its Pre-IND meeting with the FDA.
